OSI licenses diabetes drug to Lilly in $385M pact

OSI has licensed the exclusive rights to PSN010--its early-stage diabetes drug--to Eli Lilly for $25 million up front and up to $360 million in milestones plus royalty payments. The drug is designed to fight type 2 diabetes by promoting glucokinase, a protein that prompts the pancreas to make more insulin while promoting better control of glucose.

David Moller, M.D., Lilly's vice president, endocrine and cardiovascular research and clinical investigation commented: "This in-licensing agreement will help bolster Lilly's early stage pipeline and will augment one of our core therapeutic areas.

- here's the report on the pact from Newsday
-
and here's the release

Related Articles:
OSI looks to unload Macugen, exit eye diseases. Report
OSI grants licensing rights to Bristol-Myers. Release
Lilly to Icos: Merry Christmas, you're fired. Report

Suggested Articles

Bausch Health is paying $10 million upfront for the option to acquire Allegro Ophthalmics’ eye disease assets, with a promise of $40 million to come.

Anthony Coyle, Ph.D., has signed up to run Repertoire Immune Medicines’ R&D.

The IPO haul will set Kronos up to start a registrational phase 2/3 trial of a first-line AML drug licensed from Bischofberger's former employer.